WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that the U.S. Patent and Trademark Office issued U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results